May 29 – June 2, 2026 | McCormick Place, Chicago, IL
Making sense of oncology at ASCO
The ASCO Annual Meeting brings together over 40,000 oncology professionals to share breakthrough research and practice-changing data. As innovation continues to accelerate, so does the complexity of understanding what new evidence means for assets, portfolios and strategy.
At this year’s meeting, Prescient is looking forward to engaging with the latest data, emerging narratives and shifts in the competitive landscape across oncology.
With thousands of abstracts and sessions, the challenge is no longer access to information, but understanding what matters and how it should inform decision-making. We work with oncology teams to interpret the evidence, assess the implications and identify clear next steps.
Focus at ASCO 2026
During ASCO, our team will be following key developments across the oncology landscape, including new data, evolving narratives and areas of emerging importance. We will be considering how these developments may shape the broader environment and what they could mean for future clinical and strategic decision-making.
As part of our coverage of ASCO 2026, we have developed an Intelligence Brief exploring the data, competitive dynamics and emerging oncology narratives expected to define this year’s meeting. From pivotal KRAS readouts and late-breaking Phase III data to broader strategic implications across solid tumours and haematology, the report highlights the themes our team will be watching closely throughout ASCO. Complete the form below to download the brief and explore the insights likely to matter most for oncology teams in 2026.
Our oncology experience
Prescient has supported oncology teams across a wide range of strategic and evidence-based challenges, from early development through to commercialization.
- 1,500+ oncology projects delivered over 10+ years
- 250+ assets and indications supported
- Average of 7 years supporting an oncology asset
- Experience across solid tumours, haematology, specialist areas, and major modalities
Our work spans scientific insight, strategy, and stakeholder perspectives, helping teams navigate complexity at each stage of the asset lifecycle.
Meet us at ASCO
Our team will be on-site throughout the meeting, bringing a range of experience across oncology and biopharma strategy. We welcome the opportunity to discuss how the latest developments at ASCO may shape your priorities and next steps.
Jason McKenna
CEO
Debbie Allman
CGO
Ryan Caradonna
Global Practice Lead, Partner
Stephanie Hall
Global Practice Lead, Partner
Adam Hutchings
Managing Partner, Dolon (part of Prescient)
Book a meeting here: https://bookings.cloud.microsoft/book/ASCO2026Meetings@dolon.com/s/3DGCTgnCEEyrBUP8ACH6aA2?ismsaljsauthenabled
Katy Chun
Client Partner, Co-Lead Medical
Anthony Starling
Client Partner
Gordon Gochenauer
Associate Partner
Harminder Bhatia
Client Partner
Easha Ghildyal
Client Partner
Shweta Dudeja
Senior Principal
Chris Lewis-DeBoos
Associate Partner
Milagros Rojas
Principal
